TABLE II.
Progression-free (PFS) and overall survival (OS) by first-line treatment received
| First-line therapy received | PFS (months on treatment) | OS (months from line-of-therapy initiation to death) | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Line 1 | Line 2 | Line 3 | Line 1 | Line 2 | Line 3 | |
| Matched targeted therapy26 | 16 | 4 | 2 | 22.75a/26 | 10 | 6 |
|
| ||||||
| Matched immunotherapy27 | 10 | 5 | 3 | 20 | 10 | 5 |
|
| ||||||
| Chemotherapy plus immunotherapy28 | 6 | 5 | 3 | 16 | 10 | 5 |
|
| ||||||
| Chemotherapy27 | 6 | 4 | 2 | 12 | 6 | 2 |
|
| ||||||
| No treatment or palliative | 3 | 2 | 1 | 5 | 3 | 2 |
a
Conventional tests. First-line targeted therapy adjusted for delays in turnaround time.